Showing results (161-170 of 280) with videos related to

Sort By:
Pageof 28
The Lancet. Haematology|July 9, 2017
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE studyHagop M Kantarjian, Daniel J DeAngelo, Anjali S Advani, et al.
Cancer|May 13, 2016
Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemiaAmir T Fathi, Daniel J DeAngelo, Kristen E Stevenson, et al.
The Journal of Experimental Medicine|December 12, 2007
Alu elements mediate MYB gene tandem duplication in human T-ALLJennifer O'Neil, Joelle Tchinda, Alejandro Gutierrez, et al.
Leukemia|July 17, 2026
Comparison of obecabtagene autoleucel versus an external control arm in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemiaMax S Topp, Bijal D Shah, Elias Jabbour, et al.
Blood|July 27, 2018
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AMLAmir T Fathi, Harry P Erba, Jeffrey E Lancet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2013
A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targetsSophia Adamia, Benjamin Haibe-Kains, Patrick M Pilarski, et al.
NEJM Evidence|July 24, 2023
Prediction of risk for myeloid malignancy in clonal hematopoiesisLachelle D Weeks, Abhishek Niroula, Donna Neuberg, et al.
Blood|May 5, 2018
High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AMLSanjay S Patel, Frank C Kuo, Christopher J Gibson, et al.
Blood|June 5, 2004
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AMLJingrui Jiang, J Guillermo Paez, Jeffrey C Lee, et al.
Haematologica|January 8, 2026
Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemiaElias Jabbour, Karamjeet S Sandhu, Paul Shaughnessy, et al.
Pageof 28